Rhythm Pharmaceuticals Inc., of Boston, said it presented results from a phase IIa trial assessing the safety and efficacy of relamorelin (RM-131) in 48 patients with chronic constipation at the American College of Gastroenterology scientific meeting in Philadelphia.